KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 103 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,258,938 | +22.6% | 234,573 | +14.6% | 1.83% | +55.3% |
| Q2 2023 | $1,842,480 | +197.8% | 204,720 | +160.1% | 1.18% | +179.8% |
| Q1 2023 | $618,739 | +16.3% | 78,720 | 0.0% | 0.42% | +14.7% |
| Q4 2022 | $532,147 | -53.4% | 78,720 | 0.0% | 0.37% | -49.7% |
| Q3 2022 | $1,142,000 | +47.4% | 78,720 | 0.0% | 0.73% | +37.0% |
| Q2 2022 | $775,000 | -33.2% | 78,720 | 0.0% | 0.53% | -3.3% |
| Q1 2022 | $1,160,000 | +11.4% | 78,720 | 0.0% | 0.55% | +78.6% |
| Q4 2021 | $1,041,000 | -24.2% | 78,720 | 0.0% | 0.31% | -30.0% |
| Q3 2021 | $1,374,000 | -27.1% | 78,720 | 0.0% | 0.44% | -24.9% |
| Q2 2021 | $1,886,000 | – | 78,720 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |